Solifenacin Succinate Tablets, 10 mg, packaged in a) 30-count bottles (NDC 51991-894-33) and b) 9...

FDA Drug Recall #D-1051-2020 — Class II — January 24, 2020

Recall Summary

Recall Number D-1051-2020
Classification Class II — Moderate risk
Date Initiated January 24, 2020
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Breckenridge Pharmaceutical, Inc
Location Berlin, CT
Product Type Drugs
Quantity 11, 250 bottles

Product Description

Solifenacin Succinate Tablets, 10 mg, packaged in a) 30-count bottles (NDC 51991-894-33) and b) 90-count bottles (NDC 51991-894-90), Distributed by: Breckenridge Pharmaceutical, Inc. Boca Raton, FL 33487; Manufactured by: Piramal Enterprises Limited Plot No 67-70, Sector -2 Pithampur 454 775, Dist, Dhar Madhya Pradesh, INDIA

Reason for Recall

CGMP Deviations: During manufacturing Solifenacin Succinate Tablets might convert to Solifenacin Tartrate Tablets.

Distribution Pattern

Product was distributed nationwide within the United States.

Lot / Code Information

Lot #: a) 81253, 81272, Exp. Date 01/2021 and b) 81268, Exp. Date 01/2021

Other Recalls from Breckenridge Pharmaceutical, Inc

Recall # Classification Product Date
D-0387-2025 Class II Duloxetine Delayed-Release Capsules USP, 60 mg,... Apr 14, 2025
D-0388-2025 Class II Duloxetine Delayed-Release Capsules USP, 30 mg,... Apr 14, 2025
D-0161-2025 Class II Duloxetine Delayed-Release Capsules, USP, 30mg,... Dec 6, 2024
D-0162-2025 Class II Duloxetine Delayed-Release Capsules, USP, 60 mg... Dec 6, 2024
D-0009-2025 Class II Duloxetine Delayed-Release Capsules, USP, 20mg,... Oct 10, 2024

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.